However, in June 2021 Audentes Therapeutics reported the death of three patients affected by X-linked myotubular myopathy (XLMTM), who received the highest AAV dose ever used in humans (3 x 1014 vg/kg) in the context of the ASPIRO clinical trial (NCT03199469), aimed at evaluating safety and efficacy of AT132, an AAV8-delivered gene therapy (AAV8-MTM1) (69, 78). Here, MTM1 is linked to X-linked myotubular myopathy.